A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging |
Moon, Won-Jin
(Department of Radiology, Konkuk University School of Medicine)
Park, Ju-Yeon (Department of Radiology, Konkuk University School of Medicine) Yun, Won-Sung (Department of Radiology, Konkuk University School of Medicine) Jeon, Ji Yeong (Department of Radiology, Konkuk University School of Medicine) Moon, Yeon Sil (Department of Neurology, Konkuk University School of Medicine) Kim, Heejin (Department of Neurology, Konkuk University School of Medicine) Kwak, Ki-Chang (Department of Biomedical Engineering, Hanyang University) Lee, Jong-Min (Department of Biomedical Engineering, Hanyang University) Han, Seol-Heui (Department of Neurology, Konkuk University School of Medicine) |
1 | Shibata E, Sasaki M, Tohyama K, Otsuka K, Endoh J, Terayama Y, et al. Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus. Biol Psychiatry 2008;64:401-406 DOI |
2 | Song IU, Kim JS, Yoo JY, Song HJ, Lee KS. Cognitive dysfunctions in mild Parkinson's disease dementia: comparison with patients having mild Alzheimer's disease and normal controls. Eur Neurol 2008;59:49-54 DOI |
3 | Song IU, Chung YA, Chung SW, Jeong J. Early diagnosis of Alzheimer's disease and Parkinson's disease associated with dementia using cerebral perfusion SPECT. Dement Geriatr Cogn Disord 2014;37:276-285 DOI |
4 | Martorana A, Koch G. “Is dopamine involved in Alzheimer's disease?”. Front Aging Neurosci 2014;6:252 |
5 | Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184 DOI |
6 | Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707; quiz 1837 DOI |
7 | McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944 DOI |
8 | Kitao S, Matsusue E, Fujii S, Miyoshi F, Kaminou T, Kato S, et al. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies. Neuroradiology 2013;55:947-953 DOI |
9 | Kashihara K, Shinya T, Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 2011;18:1093-1096 DOI |
10 | Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011;26:1633-1638 DOI |
11 | Miyoshi F, Ogawa T, Kitao SI, Kitayama M, Shinohara Y, Takasugi M, et al. Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy. AJNR Am J Neuroradiol 2013;34:2113-2118 DOI |
12 | Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, et al. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Neuroradiology 2013;55:719-724 DOI |
13 | Sasaki M, Shibata E, Kudo K, Tohyama K. Neuromelanin-sensitive MRI: basics, technique, and clinical applications. Clin Neuroradiol 2008;18:147-153 DOI |
14 | Tosk JM, Holshouser BA, Aloia RC, Hinshaw DB Jr, Hasso AN, MacMurray JP, et al. Effects of the interaction between ferric iron and L-dopa melanin on T1 and T2 relaxation times determined by magnetic resonance imaging. Magn Reson Med 1992;26:40-45 DOI |
15 | Melki PS, Mulkern RV. Magnetization transfer effects in multislice RARE sequences. Magn Reson Med 1992;24:189-195 DOI |
16 | Lehericy S, Bardinet E, Poupon C, Vidailhet M, Francois C. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov Disord 2014;29:1574-1581 DOI |
17 | Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 2008;106:1866-1875 |
18 | Cosottini M, Frosini D, Pesaresi I, Costagli M, Biagi L, Ceravolo R, et al. MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology 2014;271:831-838 DOI |
19 | Kashihara K, Hanaoka A, Imamura T. Frequency and characteristics of taste impairment in patients with Parkinson's disease: results of a clinical interview. Intern Med 2011;50:2311-2315 DOI |
20 | Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 2001;54:414-418 |
21 | Kwon DH, Kim JM, Oh SH, Jeong HJ, Park SY, Oh ES, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267-277 DOI |
22 | Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schafer A, Peters AM, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012;35:48-55 DOI |
23 | Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The ‘swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814 DOI |
24 | Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 2013;81:534-540 DOI |
25 | Sasaki M, Shibata E, Tohyama K, Kudo K, Endoh J, Otsuka K, et al. Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications. Neuroreport 2008;19:1649-1654 DOI |
26 | Double KL, Ben-Shachar D, Youdim MB, Zecca L, Riederer P, Gerlach M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol Teratol 2002;24:621-628 DOI |
27 | Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578-580 DOI |
28 | Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17:1215-1218 DOI |
29 | Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, et al. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy. Eur Neurol 2013;70:70-77 DOI |
30 | Ohtsuka C, Sasaki M, Konno K, Kato K, Takahashi J, Yamashita F, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014;20:755-760 DOI |
31 | Kashihara K, Shinya T, Higaki F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern Med 2011;50:1683-1687 DOI |